We are live on ! Find out more
ATXS

Astria Therapeutics
ATXS

Delisted

ATXS was delisted on the 22nd of January, 2026.

Back to rankings

58 hedge funds and large institutions have $85.6M invested in Astria Therapeutics in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

168% more capital invested

Capital invested by funds: $32M → $85.6M (+$53.7M)

0.95% more ownership

Funds ownership: 7.88% → 8.83% (+0.95%)

7% less call options, than puts

Call options by funds: $269K | Put options by funds: $290K

5% less funds holding

Funds holding: 61 → 58 (-3)

15% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 20

48% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 23

Holders
58
Holders Change
-3
Holders Change %
-4.92%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
12
Reduced
23
Closed
20
Calls
$269K
Puts
$290K
Net Calls
-$21K
Net Calls Change
-$2.48M

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$12.9M
2
PA
Perceptive Advisors
New York
+$12.5M
3
FFM
Fairmount Funds Management
Pennsylvania
+$8.74M
4
CAM
Cormorant Asset Management
Massachusetts
+$7.68M
5
VA
VR Adviser
New York
+$7M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$3.74M
2
BlackRock
BlackRock
New York
-$2.13M
3
State Street
State Street
Massachusetts
-$1.06M
4
IC
Ikarian Capital
Texas
-$694K
5
Northern Trust
Northern Trust
Illinois
-$375K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$16.2M +$12.5M +958,939 +298%
RCM
2
RA Capital Management
Massachusetts
$12.6M +$12.9M +991,310 New
FFM
3
Fairmount Funds Management
Pennsylvania
$8.63M +$8.74M +673,167 +7,597%
CAM
4
Cormorant Asset Management
Massachusetts
$7.49M +$7.68M +591,667 New
VA
5
VR Adviser
New York
$6.82M +$7M +539,000 New
LGM
6
Logos Global Management
California
$6.73M +$6.9M +531,667 New
Citadel Advisors
7
Citadel Advisors
Florida
$4.13M +$4.14M +319,219 +4,482%
BC
8
Boxer Capital
California
$3.75M +$3.84M +295,833 New
CC
9
Commodore Capital
New York
$3.41M +$3.5M +269,500 New
Alyeska Investment Group
10
Alyeska Investment Group
Illinois
$2.63M +$1.12M +86,169 +71%
ACP
11
Acuta Capital Partners
California
$2.48M +$2.54M +195,612 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$1.71M -$136K -10,469 -7%
SCM
13
Soleus Capital Management
Connecticut
$1.64M – – –
IC
14
Ikarian Capital
Texas
$1.12M -$694K -53,450 -38%
Millennium Management
15
Millennium Management
New York
$974K +$999K +76,935 New
Renaissance Technologies
16
Renaissance Technologies
New York
$796K +$429K +33,067 +111%
BlackRock
17
BlackRock
New York
$497K -$2.13M -163,827 -81%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$398K -$254K -19,544 -38%
AI
19
ArchPoint Investors
Florida
$352K +$8.17K +629 +2%
TEE
20
Tibra Equities Europe
United Kingdom
$328K +$336K +25,883 New
SB
21
Samsara BioCapital
California
$317K – – –
Morgan Stanley
22
Morgan Stanley
New York
$265K +$43.4K +3,344 +19%
PPA
23
Parametric Portfolio Associates
Washington
$243K -$122K -9,379 -33%
E
24
Ergoteles
New York
$193K +$198K +15,217 New
Group One Trading
25
Group One Trading
Illinois
$180K -$34.5K -2,659 -16%
1
2 3 4

ATXS Hedge Fund Activity: Q2 2021 in Review

58 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2021, worth a combined $85.6M — up 168% from $32M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ATXS and 17 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 12 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $12.9M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.74M sold.

  • 58 institutional investors held Astria Therapeutics (ATXS) as of Q2 2021, down from 61 in Q1 2021.
  • Funds reported $85.6M of Astria Therapeutics stock for Q2 2021, up 168% quarter-over-quarter.
  • 17 funds opened new Astria Therapeutics positions in Q2 2021 and 20 closed out, a net change of -3 holders.
  • The largest Astria Therapeutics buyer in Q2 2021 was RA Capital Management, an estimated $12.9M added.
  • The largest Astria Therapeutics seller in Q2 2021 was Sphera Funds Management, an estimated $3.74M sold.

Based on aggregated 13F filings for Q2 2021.